FibroGen Q2 EPS $(0.90) Misses $(0.72) Estimate, Sales $44.32M Beat $34.17M Estimate
Portfolio Pulse from totan@benzinga.com
FibroGen reported Q2 losses of $(0.90) per share, missing the analyst consensus estimate of $(0.72) by 25%. This is a 15.38% decrease over losses from the same period last year. However, the company's quarterly sales of $44.32 million beat the analyst consensus estimate of $34.17 million by 29.70%, marking a 48.69% increase over sales from the same period last year.
August 07, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
FibroGen's Q2 earnings per share missed estimates, but sales exceeded expectations.
FibroGen's Q2 earnings per share missed the analyst consensus estimate by 25%, which could negatively impact the stock price. However, the company's sales exceeded the analyst consensus estimate by 29.70%, which could offset some of the negative impact.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100